These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34822305)

  • 21. Aggressive medullary thyroid cancer, an analysis of the Irish National Cancer Registry.
    Lennon P; Deady S; White N; Lambert D; Healy ML; Green A; Kinsella J; Timon C; O' Neill JP
    Ir J Med Sci; 2017 Feb; 186(1):89-95. PubMed ID: 27083464
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multifocality in Sporadic Medullary Thyroid Carcinoma: An International Multicenter Study.
    Essig GF; Porter K; Schneider D; Arpaia D; Lindsey SC; Busonero G; Fineberg D; Fruci B; Boelaert K; Smit JW; Meijer JA; Duntas LH; Sharma N; Costante G; Filetti S; Sippel RS; Biondi B; Topliss DJ; Pacini F; Maciel RM; Walz PC; Kloos RT
    Thyroid; 2016 Nov; 26(11):1563-1572. PubMed ID: 27604949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.
    Heilmann AM; Subbiah V; Wang K; Sun JX; Elvin JA; Chmielecki J; Sherman SI; Murthy R; Busaidy NL; Subbiah I; Yelensky R; Nangia C; Vergilio JA; Khan SA; Erlich RL; Lipson D; Ross JS; Miller VA; Shah MH; Ali SM; Stephens PJ
    Oncology; 2016; 90(6):339-46. PubMed ID: 27207748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genomic and Transcriptomic Characterization of Sporadic Medullary Thyroid Carcinoma.
    Qu N; Shi X; Zhao JJ; Guan H; Zhang TT; Wen SS; Liao T; Hu JQ; Liu WY; Wang YL; Huang S; Shi RL; Wang Y; Ji QH
    Thyroid; 2020 Jul; 30(7):1025-1036. PubMed ID: 32031055
    [No Abstract]   [Full Text] [Related]  

  • 25. Retroposed copies of RET gene: a somatically acquired event in medullary thyroid carcinoma.
    Bim LV; Navarro FCP; Valente FOF; Lima-Junior JV; Delcelo R; Dias-da-Silva MR; Maciel RMB; Galante PAF; Cerutti JM
    BMC Med Genomics; 2019 Jul; 12(1):104. PubMed ID: 31288802
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RET genotypes in sporadic medullary thyroid cancer: studies in a large Italian series.
    Fugazzola L; Muzza M; Mian C; Cordella D; Barollo S; Alberti L; Cirello V; Dazzi D; Girelli ME; Opocher G; Beck-Peccoz P; Persani L
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):418-25. PubMed ID: 18284634
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiple Endocrine Neoplasia Type 2B Associated Mixed Medullary and Follicular Thyroid Carcinoma in A Chinese Patient with RET M918T Germline Mutation.
    Qi XP; Lin GB; Chen B; Li F; Cao ZL; Zheng WH; Zhao JQ
    Endocr Metab Immune Disord Drug Targets; 2021; 21(3):554-560. PubMed ID: 32660411
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate adenocarcinoma in a young patient with multiple endocrine neoplasia 2B.
    Maqdasy S; Costes-Chalret N; Batisse-Lignier M; Baron S; Tauveron I
    Ann Endocrinol (Paris); 2018 Apr; 79(2):86-89. PubMed ID: 29530270
    [No Abstract]   [Full Text] [Related]  

  • 29. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.
    Subbiah V; Hu MI; Wirth LJ; Schuler M; Mansfield AS; Curigliano G; Brose MS; Zhu VW; Leboulleux S; Bowles DW; Baik CS; Adkins D; Keam B; Matos I; Garralda E; Gainor JF; Lopes G; Lin CC; Godbert Y; Sarker D; Miller SG; Clifford C; Zhang H; Turner CD; Taylor MH
    Lancet Diabetes Endocrinol; 2021 Aug; 9(8):491-501. PubMed ID: 34118198
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evidence of a low prevalence of RAS mutations in a large medullary thyroid cancer series.
    Ciampi R; Mian C; Fugazzola L; Cosci B; Romei C; Barollo S; Cirello V; Bottici V; Marconcini G; Rosa PM; Borrello MG; Basolo F; Ugolini C; Materazzi G; Pinchera A; Elisei R
    Thyroid; 2013 Jan; 23(1):50-7. PubMed ID: 23240926
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Qi XP; Jin BY; Li PF; Wang S; Zhao YH; Cao ZL; Yu XH; Cheng J; Fang XD; Zhao JQ
    Thyroid; 2019 Oct; 29(10):1447-1456. PubMed ID: 31364476
    [No Abstract]   [Full Text] [Related]  

  • 32. Genetic alterations in a primary medullary thyroid carcinoma and its lymph node metastasis in a patient with 15 years follow-up.
    González-Yebra B; Peralta R; González AL; Ayala-Garcia MA; de Zarate ME; Salcedo M
    Diagn Pathol; 2012 Jun; 7():63. PubMed ID: 22676344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A primer on the genetics of medullary thyroid cancer.
    Larouche V; Akirov A; Thomas CM; Krzyzanowska MK; Ezzat S
    Curr Oncol; 2019 Dec; 26(6):389-394. PubMed ID: 31896937
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of RET polymorphisms and haplotypes in the context of sporadic medullary thyroid carcinoma.
    Fernández RM; Peciña A; Antiñolo G; Navarro E; Borrego S
    Thyroid; 2006 Apr; 16(4):411-7. PubMed ID: 16646689
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Search of the p.M918T Mutation in the RET Oncogene in Mexican Adult Patients with Medullary Thyroid Carcinoma.
    Ruiz-Garcia E; Vidal-Millan S; Lopez-Yañez A; Torres JAP; Guadarrama-Orozco JA; Lino-Silva LS; Meneses-Garcia A; Astudillo-de la Vega H; Garcia MG
    Exp Clin Endocrinol Diabetes; 2017 Apr; 125(4):218-222. PubMed ID: 28166591
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does the RET variant G691S influence the features of sporadic medullary thyroid carcinoma?
    Cardot-Bauters C; Leteurtre E; Leclerc L; Vantyghem MC; Do Cao C; Wemeau JL; d'Herbomez M; Carnaille B; Barbu V; Pinson S; Pigny P;
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):506-10. PubMed ID: 18331611
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The rare intracellular RET mutation p.Ser891Ala in an apparently sporadic medullary thyroid carcinoma: a case report and review of the literature.
    Blom CB; Ceolin L; Romitti M; Siqueira D; Maia AL
    Arq Bras Endocrinol Metabol; 2012 Nov; 56(8):586-91. PubMed ID: 23295303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical significance of RET and RAS mutations in sporadic medullary thyroid carcinoma: a meta-analysis.
    Vuong HG; Odate T; Ngo HTT; Pham TQ; Tran TTK; Mochizuki K; Nakazawa T; Katoh R; Kondo T
    Endocr Relat Cancer; 2018 Jun; 25(6):633-641. PubMed ID: 29615431
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas.
    Dvorakova S; Vaclavikova E; Sykorova V; Vcelak J; Novak Z; Duskova J; Ryska A; Laco J; Cap J; Kodetova D; Kodet R; Krskova L; Vlcek P; Astl J; Vesely D; Bendlova B
    Mol Cell Endocrinol; 2008 Mar; 284(1-2):21-7. PubMed ID: 18282654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.
    Elisei R; Cosci B; Romei C; Bottici V; Renzini G; Molinaro E; Agate L; Vivaldi A; Faviana P; Basolo F; Miccoli P; Berti P; Pacini F; Pinchera A
    J Clin Endocrinol Metab; 2008 Mar; 93(3):682-7. PubMed ID: 18073307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.